Royalty Pharma - RPRX Stock Forecast, Price & News

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma Stock Up 0.1 %

Royalty Pharma stock traded up $0.03 during mid-day trading on Tuesday, hitting $43.96. The company had a trading volume of 34,106 shares, compared to its average volume of 1,902,796. The company has a current ratio of 19.22, a quick ratio of 19.22 and a debt-to-equity ratio of 0.68. The stock's 50 day moving average price is $42.23 and its two-hundred day moving average price is $40.89. Royalty Pharma has a 12 month low of $34.86 and a 12 month high of $44.75. The company has a market capitalization of $26.69 billion, a PE ratio of 57.05, a price-to-earnings-growth ratio of 1.18 and a beta of 0.28.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 15th. Stockholders of record on Friday, August 19th will be issued a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.73%. The ex-dividend date of this dividend is Thursday, August 18th. Royalty Pharma's payout ratio is currently 98.70%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group assumed coverage on Royalty Pharma in a research note on Wednesday, April 27th. They set a "buy" rating and a $56.00 target price on the stock. Scotiabank began coverage on Royalty Pharma in a research note on Friday, May 13th. They issued an "outperform" rating and a $53.00 price target on the stock. UBS Group began coverage on Royalty Pharma in a research note on Monday, June 13th. They issued a "buy" rating and a $47.00 price target on the stock. Tigress Financial upped their price target on Royalty Pharma from $52.00 to $57.00 and gave the stock a "buy" rating in a research note on Thursday, July 14th. Finally, Morgan Stanley upped their price target on Royalty Pharma from $48.00 to $51.00 and gave the stock an "overweight" rating in a research note on Monday, August 8th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $53.43.

Insider Activity

In other news, Director Rory B. Riggs sold 26,304 shares of the company's stock in a transaction on Thursday, May 19th. The stock was sold at an average price of $40.09, for a total transaction of $1,054,527.36. Following the transaction, the director now directly owns 575,408 shares of the company's stock, valued at $23,068,106.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Rory B. Riggs sold 26,304 shares of the company's stock in a transaction on Thursday, May 19th. The stock was sold at an average price of $40.09, for a total transaction of $1,054,527.36. Following the transaction, the director now directly owns 575,408 shares of the company's stock, valued at $23,068,106.72. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Terrance P. Coyne sold 30,000 shares of the company's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $43.19, for a total value of $1,295,700.00. Following the transaction, the chief financial officer now directly owns 970,000 shares in the company, valued at $41,894,300. The disclosure for this sale can be found here. Insiders have sold a total of 572,267 shares of company stock valued at $23,823,859 over the last ninety days. 24.86% of the stock is currently owned by corporate insiders.